2. Hyperosmolar Hyperglycemic State (HHS)

Quick Recap

Endocrine & Metabolic System, Protocol 2/9. Shares the DKA protocol's fluid/insulin/electrolyte framework but with distinct diagnostic criteria, epidemiology, and mortality profile.

1. Definition & Diagnostic Criteria

HHS = hyperglycemia (BG typically 600->1200 mg/dL, often >900) + hyperosmolarity (serum osmolarity 320-380 mOsm/L, often >350) + pronounced dehydration (hemodynamic instability, prerenal azotemia, decreased urine output) + neurologic changes ranging from mild lethargy to coma — with MINIMAL OR NO ketoacidosis (bicarbonate typically >18, ketones trace/small), distinguishing it fundamentally from DKA.

2. DKA vs HHS — Direct Comparison

Onset pattern is a key clinical clue: HHS develops insidiously over weeks with polyuria, polydipsia, weight loss, and progressive neurologic changes (fatigue, confusion, eventually coma) — a fundamentally different tempo from DKA's acute hours-to-days presentation, and this slow accumulation of profound dehydration explains why fluid deficits and mortality are both higher.

HHS is typically confined to type 2 diabetes (vs DKA, which occurs in both type 1 and a meaningful minority of type 2 patients).

3. Mortality and Prognosis — A Critical Distinction from DKA

HHS mortality is AT LEAST 10-FOLD HIGHER than DKA, ranging 10-20% (some sources cite up to 20-40%). Critically: mortality in HHS is most often due to the UNDERLYING PRECIPITATING CONDITION, not the metabolic derangement itself — this reframes the entire clinical priority: aggressive workup and treatment of the precipitant matters AT LEAST as much as, and arguably more than, the hyperglycemia/hyperosmolarity correction itself. Worse outcomes at extremes of age, and with coma, hypotension, or severe comorbidities at presentation.

4. Precipitating Causes

Most common: INFECTION — pneumonia (40-60% of infectious precipitants) and UTI (5-16%) predominate. Other causes: inadequate insulin treatment/noncompliance, new-onset diabetes, cardiovascular events, CVA, pancreatitis, drug/alcohol abuse, pulmonary embolism, trauma, pregnancy. Same medication contributors as DKA: corticosteroids, pentamidine, thiazide diuretics, sympathomimetics. Severity at presentation is often worsened by limited water intake in elderly or chronically ill patients — impaired thirst response or inability to self-hydrate compounds the osmotic diuresis, driving the profound dehydration characteristic of HHS.

5. Immediate Stabilization (ABCDE)

Given the insidious onset and profound dehydration, HHS patients often present sicker (more hemodynamically compromised, more neurologically impaired) than DKA patients at first contact — anticipate a more critically ill initial presentation.

Circulation: same initial resuscitation principles as DKA (two large-bore IVs, central line per same indications) — but average fluid loss in HHS may EXCEED 10L, even greater than DKA's typical 6-10L deficit.

Checklist:

6. Fluid Management (Same Framework as DKA, with HHS-Specific Emphasis)

Goal: replace total volume loss within 24-36 hours, with 50% of resuscitation fluid given in the first 8-12 hours.

Initial: 15-20 mL/kg/h 0.9% NS for the first 1-2 hours in hypotensive patients; crystalloids are the initial fluid of choice REGARDLESS of sodium level.

After initial bolus: reduce to 4-14 mL/kg/h, type determined by hemodynamics/sodium/urine output — 0.45% saline ~250-500 mL/h if sodium normal/elevated; continue isotonic saline ~250-500 mL/h if hyponatremia present.

HHS-SPECIFIC CAUTION: comorbidities (renal and cardiac dysfunction) are COMMON in this typically older population and warrant CLOSER hemodynamic monitoring than the average DKA patient — the large volume deficits that need correcting exist in direct tension with these patients' reduced cardiac/renal reserve, making this a genuinely harder fluid-balancing act than DKA.

Rapid correction of sodium/osmolality risks cerebral edema — same caution as DKA, arguably more relevant given HHS's larger absolute osmolar swings.

Large-volume 0.9% NS can cause a non-anion-gap metabolic acidosis, which can confuse the clinical picture (mimicking persistent/incompletely treated ketoacidosis) — recognize this iatrogenic acidosis pattern rather than assuming treatment failure.

Hypotonic (0.45%) saline may be appropriate AFTER volume correction in hemodynamically stable, hypernatremic patients (once corrected for hyperglycemia) — also appropriate when running concurrent potassium infusion, to maintain overall infusate isotonicity.

Once circulating volume/sodium restored (usually when glucose falls <200 mg/dL): replace remaining total body water losses SLOWLY with 5% glucose solution at 50-200 mL/h — avoiding sudden osmolarity shifts that risk cerebral edema/convulsions (more frequent in pediatric populations, but the principle applies).

Free water deficit calculation should guide replacement rate in hypernatremic patients (see Severe Electrolyte Disorders protocol for the general free water deficit formula).

7. Insulin Therapy

Same principles as DKA (IV bolus + continuous infusion, target glucose decline 50-100 mg/dL/h, transition to SC insulin with 1-2h overlap before drip discontinuation) — BUT note that volume resuscitation ALONE, even before insulin, will substantially lower glucose in HHS by improving renal perfusion and enhancing glucosuria/osmotic clearance. Some protocols favor a brief period of fluid-resuscitation-first before starting insulin in HHS specifically, given the risk that insulin-driven rapid osmolar shifts (before adequate volume repletion) may worsen hypotension or precipitate cerebral edema in this more fragile population — individualize insulin timing relative to fluid status more carefully than in typical DKA.

8. Electrolyte Management

Same framework as DKA (see that protocol Section 7-8 for full potassium/magnesium/phosphate detail) — potassium repletion principles apply identically, with the same caution that measured potassium may not reflect the (typically depleted) total body potassium status. Bicarbonate has essentially NO role in HHS given the absence of significant ketoacidosis in most cases — an even more clear-cut non-indication than in DKA.

9. Investigations

Same panel as DKA: complete metabolic panel with magnesium/phosphate, BUN/creatinine, ABG/anion gap, CBC with differential, urinalysis, serum osmolarity (central to the HHS diagnosis specifically), ECG, CXR, and AGGRESSIVE infectious/precipitant workup given HHS's precipitant-dominant mortality pattern (Section 3).

10. Organ Support

Aggressive fluid resuscitation (larger anticipated deficit than DKA); IV insulin with individualized timing relative to fluid status; electrolyte repletion; standard ICU supportive care; AGGRESSIVE, prioritized treatment of the precipitating illness given its dominant mortality contribution.

11. Consultation Matrix

12. Monitoring Framework

Same as DKA (hourly glucose, frequent electrolytes, fluid balance) PLUS closer hemodynamic monitoring given common comorbidities, more frequent/intensive neurologic assessment given higher rates of coma/seizure, serum osmolarity trending as a primary resolution marker alongside glucose.

13. Complications

Same electrolyte/cerebral edema risks as DKA, PLUS higher baseline risk of: seizure, coma, thromboembolism (HHS's profound dehydration/hyperviscosity state carries elevated VTE risk — consider prophylactic anticoagulation once bleeding risk allows), cardiovascular decompensation from large-volume resuscitation in a comorbid-heavy population, and death from the underlying precipitant itself (the dominant mortality driver). Prevention: aggressive precipitant identification/treatment as a co-equal priority to metabolic correction, careful individualized fluid balancing in cardiac/renal-impaired patients, VTE prophylaxis consideration. Rescue: standard DKA-shared rescue measures, escalated critical care support for the underlying precipitant.

14. Escalation & De-escalation

Escalate: hemodynamic instability, coma, or comorbidity decompensation during fluid resuscitation -> ICU-level monitoring/support, reassess fluid rate/type.

De-escalate: osmolarity/glucose normalizing, hemodynamically stable, neurologic status improving, precipitant identified/treated -> transition to SC insulin, standard floor-level monitoring.

15. ICU Discharge Criteria

Osmolarity and glucose normalized/normalizing, hemodynamically stable, neurologic status returned to baseline or a defined stable state, precipitating illness identified and on a definitive treatment course, transitioned to SC insulin appropriately, VTE prophylaxis in place.

16. Documentation & Medicolegal Checklist

17. Key Guidelines

Dhatariya KK, Vellanki P. Treatment of DKA/HHS: novel advances in the management of hyperglycemic crises (UK versus USA). Curr Diab Rep. 2017;17(5):33.

18. Controversies

Optimal timing of insulin initiation relative to fluid resuscitation in HHS specifically (fluids-first vs concurrent) is not rigidly standardized and reflects individualized clinical judgment given this population's comorbidity burden. VTE prophylaxis timing/threshold in the profound-dehydration/hyperviscosity state of HHS is not addressed by dedicated trial evidence, leaving practice variation. The relative contribution of metabolic derangement vs precipitant to HHS mortality, while clearly precipitant-dominant, does not have a precise quantified breakdown to guide resource allocation between the two management priorities.

19. References

1. Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State chapter. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 31).
2. Talekar S, Shukla U. Diabetic Emergencies. ICU Protocols: A Step-wise Approach, 2nd ed. Springer; 2020 (Ch. 5).
3. Dhatariya KK, Vellanki P. Treatment of DKA/HHS: UK versus USA. Curr Diab Rep. 2017;17(5):33.
4. Dingle HE, Slovis C. Diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome management. Emerg Med. 2018;50(8):161-171.
5. Magee MF, Bhatt BA. Management of decompensated diabetes: DKA and HHS. Crit Care Clin. 2001;17(1):75-106.

See also: Diabetic Ketoacidosis (Endocrine & Metabolic System) for the shared insulin/electrolyte management framework this protocol builds upon.